Jennifer Werely
Neurology · Greenwich, CTNPI 1225265028
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,300 of the $9,821 with a category attached, or 64.2%. AbbVie accounts for 80.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $3,998 and has fallen 86.1% since, to $557 in 2025.
Across 179 payments — averaging $54.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Pfizer$533
- SK Life Science, Inc.$491
- Lilly USA, LLC$281
- UCB, Inc.$158
- Amneal Pharmaceuticals LLC$125
- plus $330 from 5 others
What the payments were for
- Speaking & faculty fees$6,30064%
- Food & beverage$3,52136%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 98 | $7,903 |
| Pfizer | 42 | $533 |
| SK Life Science, Inc. | 7 | $491 |
| Lilly USA, LLC | 18 | $281 |
| UCB, Inc. | 3 | $158 |
| Amneal Pharmaceuticals LLC | 1 | $125 |
| Si-bone, Inc. | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Novartis | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,821 in reported general payments places this provider in the 75th percentile of 280 neurology providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 16 | $26,594 |
| Emgality SyringeGalcanezumab-Gnlm | 13 | $21,084 |
| QuliptaAtogepant | 14 | $14,770 |
| Emgality PenGalcanezumab-Gnlm | 20 | $13,868 |
| Memantine Hcl ErMemantine Hcl | 127 | $10,213 |
| NayzilamMidazolam | 13 | $8,485 |
| Memantine Hcl | 74 | $3,217 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 67 | $2,184 |
| Donepezil Hcl | 80 | $1,041 |
| Gabapentin | 63 | $778 |
| Sertraline Hcl | 75 | $778 |
| Levetiracetam | 29 | $747 |
| Lorazepam | 41 | $561 |
| Zonisamide | 40 | $544 |
| RizatriptanRizatriptan Benzoate | 20 | $504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $533 | $26,59416 claims |
| AbbVieQulipta | $7,903 | $14,77014 claims |
| UCB, Inc.Nayzilam | $158 | $8,48513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 280 neurology providers in Connecticut.
Other neurology in Greenwich
- Matthew McConnellGreenwich$15K
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
- Duarte MachadoCheshire$426K
- Tanya BilchikEast Hartford$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.